Product Information
LITHIUM 8 MEQ/5 ML SOLUTION is a generic product labeled by Advagen Pharma Ltd., priced at $0.4534 per ML under NDC 72888017246. Its NADAC has been published 59 times since Aug 20, 2025.
FDA first approved this application on Aug 14, 2023. Its Orange Book therapeutic-equivalence code is AA.
Strength
8 meq/5mL
Manufacturer
Advagen Pharma Ltd.NDC
72888017246
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LITHIUM CITRATEApproval Type
Generic (ANDA)
FDA Application
ANDA218036FDA Approved
8/14/2023
TE Code
AA
On Market Since
11/9/2022
Pharmacological Classes
Price Statistics
The NADAC for LITHIUM 8 MEQ/5 ML SOLUTION has been published 59 times since Aug 20, 2025, and over the history we have for it it has declined 3.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4534 per ML |
|---|---|
| All-time high | $0.4808 (May 13, 2026) |
| All-time low | $0.4534 (Sep 23, 2026) |
| 52-week high | $0.4808 |
| 52-week low | $0.4534 |
| Median price | $0.4758 |
| Average price | $0.4749 |
| Largest weekly change | -3.4% (Sep 23, 2026) |
| Weeks tracked | 59 |
| Tracking since | Aug 20, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Lithium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Advagen Pharma Ltd. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Lithium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Mood Stabilizer class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LITHIUM 8 MEQ/5 ML SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for LITHIUM 8 MEQ/5 ML SOLUTION, manufactured by Advagen Pharma Ltd., is $0.4534 per ML (NDC 72888017246), effective Sep 30, 2026.
How has the price of LITHIUM 8 MEQ/5 ML SOLUTION changed over time?
Over the history we have for it, the NADAC for LITHIUM 8 MEQ/5 ML SOLUTION has declined 3.5%. It has been tracked across 59 weekly CMS publications since Aug 20, 2025.
What are the highest and lowest recorded NADAC prices for LITHIUM 8 MEQ/5 ML SOLUTION?
Since Aug 20, 2025, the NADAC for LITHIUM 8 MEQ/5 ML SOLUTION has ranged from a low of $0.4534 (Sep 23, 2026) to a high of $0.4808 (May 13, 2026), with a median of $0.4758 per ML.
Are there cheaper alternatives to LITHIUM 8 MEQ/5 ML SOLUTION?
No other NADAC-published product currently shares the active ingredient and strength of LITHIUM 8 MEQ/5 ML SOLUTION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LITHIUM 8 MEQ/5 ML SOLUTION?
LITHIUM 8 MEQ/5 ML SOLUTION (NDC 72888017246) is labeled by Advagen Pharma Ltd., and CMS classifies it as a generic product.